Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

102
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
102
Hypersensitivities01:30

Hypersensitivities

8.0K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
8.0K
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

80
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
80
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

81
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
81
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

73
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
73
Varicose Veins II: Diagnostic Studies and Interprofessional Care01:26

Varicose Veins II: Diagnostic Studies and Interprofessional Care

265
Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
265

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter to the editor in response to "Rare presentation of lues maligna and nodular syphilis in an immunocompetent patient".

JAAD case reports·2026
Same author

From Conundrums to Consensus: Addressing Gaps in the Management of Leprosy.

The American journal of tropical medicine and hygiene·2026
Same author

Leprosy literature in India: A journey through history and contemporary insights.

Indian journal of dermatology, venereology and leprology·2025
Same author

Sexually transmitted infections in the elderly: A growing concern in geriatric care.

Indian journal of sexually transmitted diseases and AIDS·2025
Same author

Response to "syndromic diagnosis, sexual behavior, and management in rural population among all cases attending sexually transmitted infection clinic in a tertiary care center from the east-central zone of India: A retrospective study".

Indian journal of sexually transmitted diseases and AIDS·2025
Same author

Letter in response to "Risk factors associated with increasing prevalence of gonorrhea and the antimicrobial susceptibility profiles of <i>Neisseria gonorrhoeae</i> among adolescents: A decade-long, hospital-based study from India".

Indian journal of sexually transmitted diseases and AIDS·2025

Related Experiment Video

Updated: Mar 7, 2026

Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases
04:25

Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases

Published on: November 8, 2024

2.4K

Delayed Cutaneous Hypersensitivity Responses in Patients with Warts.

Bhushan Kumar, Surrinder Kaur, Anil Narang

    Indian Journal of Dermatology, Venereology and Leprology
    |February 21, 2017
    PubMed
    Summary

    Patients with viral warts showed weakened immune responses to various antigens, including recall antigens, DNCB, and croton oil, compared to healthy individuals. This suggests an impaired cellular immunity in individuals suffering from warts.

    More Related Videos

    Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
    11:49

    Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

    Published on: May 2, 2013

    16.7K
    Development of an IFN-&#947; ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
    08:04

    Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

    Published on: July 9, 2014

    16.4K

    Related Experiment Videos

    Last Updated: Mar 7, 2026

    Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases
    04:25

    Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases

    Published on: November 8, 2024

    2.4K
    Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
    11:49

    Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

    Published on: May 2, 2013

    16.7K
    Development of an IFN-&#947; ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
    08:04

    Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

    Published on: July 9, 2014

    16.4K

    Area of Science:

    • Immunology
    • Dermatology
    • Virology

    Background:

    • Viral warts are benign skin growths caused by human papillomaviruses.
    • Cellular immunity plays a crucial role in controlling viral infections, including those causing warts.

    Purpose of the Study:

    • To investigate the immune status of patients with viral warts.
    • To compare the immune responses to various antigens in patients with warts versus controls.

    Main Methods:

    • Twenty-five patients with viral warts were tested.
    • Immune responses were evaluated using secondary (recall) antigens, primary delayed (DNCB), and inflammatory (croton oil) antigens.

    Main Results:

    • Patients with viral warts exhibited significantly depressed immune responses to the tested antigens.
    • A notable difference in immune reactivity was observed when comparing wart patients to control groups.

    Conclusions:

    • Viral wart patients demonstrate impaired cellular immune function.
    • These findings highlight a potential link between weakened immunity and the development or persistence of viral warts.